Building on the success of its launch last year SMi Group are proud to presents the 2ndInjectable Drug Delivery Conference and exhibition. Conference Overview: The global injectable drug delivery market is expected to grow from […]
Otsuka America and Click Therapeutics have signed a collaboration agreement for the development and commercialization of a prescription digital therapeutic to treat major depressive disorder (MDD). This collaboration will leverage Click’s demonstrated ability to discover […]
SMi presents its 13th annual Parallel Trade conference happening next month. The highly anticipated event provides the perfect platform for industry experts to come together and share perspectives on the practice of parallel trade. The […]
The US Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for the manufacturing process of second generation Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo]. Andexxa received both U.S. Orphan Drug and […]
Deciphera Pharmaceuticals has initiated an open-label, multicenter, phase 1b/2 study of rebastinib, the company’s investigational small molecule switch control inhibitor of TIE2 kinase, in combination with carboplatin in patients with advanced or metastatic solid tumors. […]